Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
FRAMINGHAM, Mass., April 17, 2018 -- Clinical Laserthermia Systems Americas, Inc. (CLS Americas) a subsidiary of CLS AB in Lund, Sweden, today announced the commencement of a clinical study with Toronto General Hospital in Canada investigating MRI-guided, focal laser ablation (FLA) treatments for prostate cancer. The study has been approved by Health Canada and its results will be published on the National Institute of Health Web site: www.clinicaltrials.gov.
Starting in April 2018, twenty-five patients will participate in a 24-month study at the hospital to evaluate the safety and efficacy of CLS’s TRANBERG®|Thermal Therapy System and single-use accessories. The study includes men with early stage prostate cancer that have not already undergone radiation or hormone treatment.
“We are very pleased Toronto General Hospital has chosen our minimally invasive TRANBERG Thermal Therapy System for this important clinical study,” stated Lars-Erik Eriksson, CEO of Clinical Laserthermia Systems AB. “The study will produce important data surrounding the performance and efficacy of the TRANBERG Thermal Therapy System for MRI guided focal laser ablation treatments.”
Unique, Non-Cooled, Diffusing Fiber Technology
CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times.
About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially-designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.
The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).
Media Contact TopSpin Communications Joe Waldygo P: 480-363-8774 E: [email protected] Company Contact CLS Americas, Inc. Alan Weinberg, General Manager P: 508-620-4521 E: [email protected]
